TABLE OF CONTENTS

- Description p.1
- Abstracting and Indexing p.1
- Editorial Board p.1
- Guide for Authors p.4

DESCRIPTION

The journal aims to promote high quality research and serve as a platform for dissemination of scientific information in pediatric hematology oncology with focus on research emanating from India and surrounding countries in the subcontinent, South Asia, West and East Asia, Africa, and serve as an alternative destination for Australia, Europe and the Americas to become a truly global and representative publication. The journal intends to be a one-stop resource for cutting edge research in all matters related to Pediatric Hematology and Oncology including Hematology Medical oncology Surgical oncology Radiation oncology Imaging sciences Hemato-pathology Surgical pathology Epidemiology PHOJ invites original research papers, reviews, case reports and letters to the editor for publication which would interest a wide cross section of sub specialists and general pediatricians involved in treating children with hematological and oncological disorders.

Author benefits:
Authors do not have to pay any open access publication fee. We also provide many author benefits, such as free PDFs, special discounts on Elsevier publications and much more. Please click here for more information on our author services. Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit the Elsevier Support Center.

ABSTRACTING AND INDEXING

Scopus
Directory of Open Access Journals (DOAJ)

EDITORIAL BOARD

Editor-in-Chief
Deepak Bansal, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Pediatric Hematology-Oncology

Founding Editor-in-Chief
Gaurav Narula, Tata Memorial Hospital, Pediatric Hemato-Lymphoid Group, Mumbai, India
Myeloid Malignancies, Histiocytic Disorders, Lymphoid Malignancies

Associate Editor
Vikramjit Kanwar, Homi Bhabha Cancer Hospital, Varanasi, India
Solid Tumors - Medical Oncology, Neuro-oncology
Satya Yadav, Medanta The Medicity, Gurgaon, India
Stem Cell Transplant and Supportive Care
Nita Radhakrishnan, Post Graduate Institute of Child Health, Noida, India
Immuno- Hematology

Assistant Editors
Shweta Bansal, Dr Balabhai Nanavati Hospital, Mumbai, India
Hematological Malignancies and Stem Cell Transplant
Maya Prasad, Tata Memorial Hospital, Mumbai, India
Pediatric Solid Tumors, Late Effects

Section Editors
Ramandeep Singh Arora, Max Super Speciality Hospital Saket, New Delhi, India
Epidemiology, Quality of Life and Late Effects
Sameer Bakhshi, All India Institute of Medical Sciences, Department of Medical Oncology, New Delhi, India
Bone and Soft Tissue Sarcomas
Deepak Bansal, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Red Blood Cell Disorders
Sunil Bhat, Narayana Health Hospital, Bengaluru, Karnataka, India
Lymphoid and Myeloid Malignancies
Vineeta Gupta, Banaras Hindu University, Varanasi, India
Transfusion Medicine
Sandeep Jain, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
Bone and Soft Tissue Sarcomas
Nehal Khanna, Tata Memorial Hospital, Mumbai, India
Radiation Oncology
Nitin James Peters, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Solid Tumors - Surgical Oncology
Sajid Qureshi, Tata Memorial Hospital, Mumbai, India
Solid Tumors - Surgical Oncology
Revathi Raj, Apollo Hospitals Chennai Greens Road, Chennai, India
Stem Cell Transplantation
PG Subramanian, Tata Memorial Hospital, Mumbai, India
Hematopathology and Molecular Biology
Amita Trehan, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Thrombosis and Hemostasis

Managing Editor
Pritam Singha Roy, Tata Medical Center, Kolkata, India
Paediatric Haemato-Oncology

Social Media Editor
Kalasekhar Vijayasekharan, Regional Cancer Centre, Thiruvananthapuram, India
Pediatric Oncology

International Advisory Board
Uma Athale, McMaster University, Hamilton, Canada
Leukemia, Lymphoma, Hemoglobinopathy, Supportive care, Thrombosis in cancer, Epidemiology,
Global Health and International Pediatric hematology/Oncology
Rajat Bhattacharya, KK Women's and Children's Hospital, Singapore, Singapore
Leukaemia, Lymphoma, Stem cell transplant, Benign Haematology
Murali Chintagumpala, Texas Children’s Hospital, Houston, United States of America
Neurooncology/Solid Tumors/Retinoblastoma
Mohammad Faranoush, Hazrat-e Rasool General Hospital, Tehran, Iran
Pediatric Hematology Oncology
Amar Gajjar, St. Jude Children’s Research Hospital, Memphis, United States of America
Neuro Oncology
Rejin Kebudi, IU Oncology Institute Pediatric Hematology Oncology Service and Polyclinic, İstanbul, Turkey
Pediatric solid tumors, lymphomas, acute lymphoblastic leukemia
Gili Kenet, National Hemophilia Center, Institute of Thrombosis & Hemostasis Sheba Medical Center, Tel Aviv, Israel
Neonatal Hemostasis, Hemophilia And Rare Bleeding Disorders, Pediatric Thrombosis And Anticoagulant Therapy
Chi-kong Li, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Paediatric haematology and oncology

Nalini Pati, Canberra Hospital, Canberra, Australia
Haemato-Oncology, Leukaemia, Lymphoma, Bleeding Disorders

Koneti Rao, National Institutes of Health, Bethesda, United States of America
Pediatric Hematology, Genetics, Clinical Immunology

Howard C. Scott, The University of Tennessee Health Science Center, Memphis, United States of America
Hematologic cancers and oncology supportive care

Raj Warrier, University of Queensland, Brisbane, Australia
Pediatric Hematology
GUIDE FOR AUTHORS

NOTE
Changes in the requirements for each article types were made on 15th November 2022

INTRODUCTION

Types of paper
Contributions falling into the following categories will be considered for publication: Original Research Papers, Reviews (Narrative or Systematic or metanalyses), short communications, case reports, case series and Letters to the Editor. Please ensure that you select the appropriate article type from the list of options when making your submission. Authors contributing to special issues should ensure that they select the special issue article type from this list.

Original research articles
Articles submitted under this category should represent original studies involving any aspect of clinical or laboratory investigation. These articles must have text shorter than 3500 words, excluding references and abstract. There is no upper limit to the maximum number of authors allowed as long as justification can be provided.

Title: Title of the article should be short, yet sufficiently informative so as to be useful in indexing and information retrieval.

Abstract: The abstracts should be brief (up to 250 words) and structured to contain the following subheadings - Background, Material and methods, results and conclusion.

Key Words: Three to six key words.

Main Text: The text of the article is to be under the following headings. Please note that all headings are mandatory and need to be in the same sequence. Introduction Material and Methods: Please include "Trial registration number" in case of clinical trials Results Discussion Conclusion Patient's/ Guardian's consent: Consent is required if you are using patient's details in any format (text or an image -clinical, radiographic or histopathologic). Please write "Not applicable" if there was no requirement of this Ethical clearance: It is mandatory for the authors to declare that "Ethics approval or waiver has been obtained with their letter number... dated...". Please write "Not required" if there was no requirement of this. Funding - If no funding has been provided for the research, it is recommended to include the following sentence: "This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors." Declaration of competing interest: Please write "None" if there are no conflict of interest to declare Acknowledgments: Please write "None" if there are no acknowledgements References: Number of references can be as per need

Reviews (Narrative or Systematic or metanalyses)
Reviews should focus on the critical aspects of a subject, linking what is known to what areas remain controversial or unanswered. All types of reviews should be limited to 3500 words (excluding abstract and references). There is no upper limit to the maximum number of authors allowed as long as justification can be provided.

(a) Systematic reviews and meta-analyses: Must adhere to the guidelines provided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses report (PRISMA Statement). Suggested guidelines to follow: Microsoft Word - PRISMA 2009 Checklist.doc (prisma-statement.org)

Title: In cases of systematic review the title should Identify the report as a systematic review.

Abstract: 250 words Structured with following headings - Background, Methods (should include Data sources; Study eligibility criteria; Participants; Interventions; Statistical analysis), Results, Conclusion.

Keywords: 3 to 6 Keywords

Main Text: The text of the article is to be under the following headings. Please note that all headings are mandatory and need to be in the same sequence.

Introduction Material and Methods: For systematic reviews include all sub-headings as per PRISMA guidelines Results Discussion Conclusion Patient's/ Guardian's consent: Consent is required if you are using patient's details in any format (text or an image -clinical, radiographic or histopathologic). Please write "Not applicable" if there was no requirement of this. Ethical clearance: It is mandatory for the authors to declare that "Ethics approval or waiver has been obtained with their letter number... dated...". Please write "Not required" if there was no requirement of this. Funding - If no funding has
been provided for the research, it is recommended to include the following sentence: "This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors." Declaration of competing interest: Please write "None" if there are no conflict of interest to declare Acknowledgments: Please write "None" if there are no acknowledgements References: Number of references can be as per need

**Figures and Tables:** The article should have a maximum of 8 tables and, or figures. For systematic review- Must include a flow diagram as per PRISMA guidelines

(a) Narrative reviews
**Title:** Concise, yet informative. Can include the word "Review" to make it more informative.
**Abstract:** 250 words unstructured
**Keywords:** 3 to 6 Keywords
**Main Text:** The text of the article is to be under the following headings. Please note that all headings are mandatory and need to be in the same sequence. Introduction Main body of text - This need not be the exact heading; rather you may choose a suitable heading as per need Conclusion Patient's/ Guardian's consent: Consent is required if you are using patient's details in any format (text or an image - clinical, radiographic or histopathologic). Please write "Not applicable" if there was no requirement of this Ethical clearance: It is mandatory for the authors to declare that "Ethics approval or waiver has been obtained with their letter number... dated...". Please write "Not required" if there was no requirement of this. Funding: If no funding has been provided for the research, it is recommended to include the following sentence: "This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors." Declaration of competing interest: Please write "None" if there are no conflict of interest to declare Acknowledgments: Please write "None" if there are no acknowledgements References: Number of references can be as per need

Figures and Tables: The article should have a maximum of 8 tables and, or figures.

**Letters to the Editor**
Letters to the Editor can be submitted in reference to previously published manuscripts in PHOJ. It should be limited in length to 500 words and may include not more than 10 references and 2 tables and/or figures.
**Title:** Letters to the editor that provide a comment on a published article should be titled: "Comment on: [Title of article being commented upon]" The authors may add a subtitle if they wish to make a specific point. The authors' reply should be titled: "Reply to: Comment on: [Title of article being commented upon]"
**Abstract:** Not required
**Keywords:** 3 to 6 Keywords
**Main text:** The text of the article is to be under the following headings. Please note that all headings are mandatory and need to be in the same sequence. Should begin with - "Dear Editor" followed by main body of text. Patient's/ Guardian's consent: Consent is required if you are using patient's details in any format (text or an image -clinical, radiographic or histopathologic). Please write "Not applicable" if there was no requirement of this. Ethical clearance: It is mandatory for the authors to declare that "Ethics approval or waiver has been obtained with their letter number... dated...". Please write "Not required" if there was no requirement of this. Funding: If no funding has been provided for the research, it is recommended to include the following sentence: "This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors." Declaration of competing interest: Please write "None" if there are no conflict of interest to declare Acknowledgments: Please write "None" if there are no acknowledgements References: Number of references can be maximum 10

Figures and Tables: The article should have a maximum of 2 tables and, or figures.

**Short Communication**
Short communications can be personal opinions, or mini review on a burning topic, related to journal's scope. Word limit can be up to 1000 words (excluding abstract and references). There is no upper limit to the maximum number of authors allowed as long as justification can be provided.
**Title:** Concise, yet informative.
**Abstract:** Abstract 150 words, unstructured
**Keywords:** 3 to 6 Keywords
Main text: The text of the article is to be under the following headings. **Please note that all headings are mandatory and need to be in the same sequence.** Can be written in a free flow with suitable headings where needed Patient's/Guardian's consent: Consent is required if you are using patient's details in any format (text or an image -clinical, radiographic or histopathologic). Please write "Not applicable" if there was no requirement of this. Ethical clearance: It is mandatory for the authors to declare that "Ethics approval or waiver has been obtained with their letter number... dated...". Please write "Not required" if there was no requirement of this. Funding: If no funding has been provided for the research, it is recommended to include the following sentence: "This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors." Declaration of competing interest: Please write "None" if there are no conflict of interest to declare Acknowledgments: Please write "None" if there are no acknowledgements References: Number of references can be as per need

Figures and Tables: The article should have a maximum of 6 tables and, or figures.

**Case Report or Case Series**
These should be rare, unique or novel, describing a pathology, or management of a case. Case report can include description of up to 3 cases. Word limit can be up to 1500 words (excluding abstract and references). Case series is recommended for description of 4 or more than 4 rare, unique or novel cases and word limit can be up to 2000 words (excluding abstract and references). There is no upper limit to the maximum number of authors allowed as long as justification can be provided.

**Title:** Concise, yet informative. It is suggested to include the diagnosis or intervention of primary focus followed by the words "case report" or "case series" as applicable

**Abstract:** Structured abstract of 150 words with following sub headings- Background, Case report, Conclusion

**Keywords:** 3 to 6 Keywords

**Main text:** The text of the article is to be under the following headings. **Please note that all headings are mandatory and need to be in the same sequence.**

Introduction

Case Report/Case series - As applicable Discussion

Patient's/Guardian's consent: Consent is required if you are using patient's details in any format (text or an image -clinical, radiographic or histopathologic). Please write "Not applicable" if there was no requirement of this. Ethical clearance: It is mandatory for the authors to declare that "Ethics approval or waiver has been obtained with their letter number... dated...". Please write "Not required" if there was no requirement of this. Funding: If no funding has been provided for the research, it is recommended to include the following sentence: "This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors." Declaration of competing interest: Please write "None" if there are no conflict of interest to declare Acknowledgments: Please write "None" if there are no acknowledgements References: Number of references can be up to 30

**BEFORE YOU BEGIN**

**Ethics in publishing**
Please see our information on Ethics in publishing.

**Ethical approval of studies and Informed consent**
Studies involving human subjects or animals should have received the approval of the institutional ethics committee. A statement to this effect and that informed consent was obtained from participating human subjects must be included in the manuscript text. Please ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/; EU Directive 2010/63/EU for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm; Uniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

**Declaration of interest**
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two...
places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this: 'Declarations of interest: none'. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal’s official records. It is important for potential interests to be declared in both places and that the information matches. More information.

**Declaration of generative AI in scientific writing**
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier’s AI policy for authors.

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

**Disclosure instructions**
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.

Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

**Submission declaration and verification**
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify compliance, your article may be checked by Crossref Similarity Check and other originality or duplicate checking software.

**Use of inclusive language**
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.
Reporting sex- and gender-based analyses

Reporting guidance
For research involving or pertaining to humans, animals or eukaryotic cells, investigators should integrate sex and gender-based analyses (SGBA) into their research design according to funder/sponsor requirements and best practices within a field. Authors should address the sex and/or gender dimensions of their research in their article. In cases where they cannot, they should discuss this as a limitation to their research's generalizability. Importantly, authors should explicitly state what definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility of their research and to avoid ambiguity or conflation of terms and the constructs to which they refer (see Definitions section below). Authors can refer to the Sex and Gender Equity in Research (SAGER) guidelines and the SAGER guidelines checklist. These offer systematic approaches to the use and editorial review of sex and gender information in study design, data analysis, outcome reporting and research interpretation - however, please note there is no single, universally agreed-upon set of guidelines for defining sex and gender.

Definitions
Sex generally refers to a set of biological attributes that are associated with physical and physiological features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. Sex and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging whereas these constructs actually exist along a spectrum and include additional sex categorizations and gender identities such as people who are intersex/have differences of sex development (DSD) or identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important for authors to define the manner in which they are used. In addition to this definition guidance and the SAGER guidelines, the resources on this page offer further insight around sex and gender in research studies.

Author contributions
For transparency, we require corresponding authors to provide co-author contributions to the manuscript using the relevant CRediT roles. The CRediT taxonomy includes 14 different roles describing each contributor's specific contribution to the scholarly output. The roles are: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; and Writing - review & editing. Note that not all roles may apply to every manuscript, and authors may have contributed through multiple roles. More details and an example.

Authorship
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

Changes to authorship
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

Before the accepted manuscript is published: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.
After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

Copyright
Upon successful submission of an article, authors will be asked to complete a 'Journal Publishing Agreement'. Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement. Submission of this form is essential to initiate the peer review process.

Permission of the society is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult editor.phoj@gmail.com). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article.

Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Open Access
Every peer-reviewed research article appearing in this journal will be published open access. This means that the article is universally and freely accessible via the internet in perpetuity, in an easily readable format immediately after publication. The author does not have any publication charges for open access. Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics will pay to make the article open access. A CC user license manages the reuse of the article (see https://www.elsevier.com/openaccesslicenses). All articles will be published under the following license:

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement it is recommended to state this. If no funding has been provided for the research, it is recommended to include the following sentence: "This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors."
Please see https://www.elsevier.com/funding.

Open access
Please visit our Open Access page for more information about open access publishing in this journal.

Elsevier Researcher Academy
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the Language Editing service available from Elsevier's Language Services.
**Submission**  
Submission to this journal proceeds totally online. Use the following guidelines to prepare your article. Via the homepage of this journal (https://www.editorialmanager.com/PHOJ/default.aspx) you will be guided stepwise through the creation and uploading of the various files. The system automatically converts source files to a single Adobe Acrobat PDF version of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor’s decision and requests for revision, takes place by e-mail and via the author’s homepage, removing the need for a hard-copy paper trail. If you are unable to provide an electronic version, please contact the editorial office prior to submission by writing to editor.phoj@gmail.com.

**Additional Information**  
Tables and figures may be presented with captions within the main body of the manuscript; if so, figures should additionally be uploaded as high resolution files.

**PREPARATION**  

**Queries**  
For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our Support Center.

**Double anonymized review**  
This journal uses double anonymized review, which means the identities of the authors are concealed from the reviewers, and vice versa. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal’s usual procedures, with peer review handled independently of the relevant editor and their research groups.

**Special Issues and Article Collections**  
The peer review process for Special Issues and Article Collections is also a single anonymized review process. All contributions will be initially assessed by the Editor-in-chief for suitability for the journal. Papers deemed suitable are then assigned to an external Guest Editor. All Guest Editors receive training on conducting peer review. The Guest Editor sends the manuscript to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Guest Editor makes a recommendation for the decision to the Editor in Chief. The Editor in Chief is responsible for the final decision regarding acceptance or rejection of articles. The Editor in Chief oversees the peer review process of all Special Issues and Articles Collections to ensure the high standards of publishing ethics and responsiveness are respected. Guest Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the guest editor has an interest. Any such submission is subject to all of the journal’s usual procedures, with peer review handled independently of the relevant editor and their research groups.

**Use of word processing software**  
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor’s options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

**Article structure**
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Hypothesis (Optional)
A hypothesis should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work.

Results
Results should be clear and concise.

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Highlights
Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).
**Abstract**
A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

**Keywords**
Authors are invited to submit keywords associated with their paper.

**Abbreviations**
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

**Acknowledgements**
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

**Nomenclature and units**
Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. Authors wishing to present a table of nomenclature should do so on the second page of their manuscript.

**Math formulae**
Present simple formulae in the line of normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

**Footnotes**
Footnotes should be used sparingly. Number them consecutively throughout the article, using superscript Arabic numbers. Many wordprocessors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

**Table footnotes**
Indicate each footnote in a table with a superscript lowercase letter.

**Artwork**

**Electronic artwork**

**General points**
- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.
- Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

**Formats**
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

**EPS (or PDF):** Vector drawings, embed all used fonts.

**TIFF (or JPEG):** Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

**TIFF (or JPEG):** Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

**TIFF (or JPEG):** Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

**Please do not:**
- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

**Color artwork**
Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version.

**Figure captions**
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

**Tables**
Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

**References**

**Citation in text**
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

**Web references**
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

**Preprint references**
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

**References in a special issue**
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.
**Reference management software**

This journal has standard templates available in key reference management packages EndNote (http://www.endnote.com/support/enstyles.asp) and Reference Manager (http://refman.com/support/rmstyles.asp). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

**Reference style Please make this as per the selected system- Vancouver- numerals in text only**

**Reference style**

Indicate references by number(s) in square brackets in line with the text. Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

**List of references**

List up to 6 authors. For references with more than 6 authors the first 6 should be listed followed by 'et al'. Note shortened form for last page number. e.g., 51-9. For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927-34) (see also Samples of Formatted References).

Numbers should be in order of appearance in the text. Only references in the abstract should be cited with first author(s) name and year as already specified. Any reference first so mentioned in the abstract, should also be brought into the text at appropriate place and given a number in order of appearance.

All References should then be serially listed under the heading "References", which should appear after the "Acknowledgements" section.

**Reference style**

**Text:** Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

**List:** Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

**Examples:**

**Reference to a journal publication:**


**Reference to a journal publication with an article number:**


**Reference to a book:**


**Reference to a chapter in an edited book:**


**Reference to a website:**


**Reference to a dataset:**

[6] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. https://doi.org/10.17632/xwj98nb39r.1. Note shortened form for last page number. e.g., 51-9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927-34) (see also Samples of Formatted References).

**Journal abbreviations source**

Journal names should be abbreviated according to


List of title word abbreviations: http://www.issn.org/2-22661-LTWA-online.php;

Editorial Process
All articles submitted to the Journal undergo initial review by the Editor/associate editor and articles that are outside the scope of Journal or are not in the journal format are excluded. Later each article is reviewed by at least two reviewers. The time to first decision is usually less than 6 weeks. As per the policy of the Journal, an Editor, who is either author of a manuscript or belongs to the same institution as any of the authors, is not assigned that manuscript and is not involved in decision making regarding its publication. Reviewers/Editorial Board members should decline the invitation to review a manuscript which is submitted by authors from their institution.

Submission checklist
The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

Ensure that the following items are present:
One Author designated as corresponding Author:
• E-mail address
• Full postal address
• Telephone and fax numbers
All necessary files have been uploaded
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been "spellchecked" and "grammar-checked"
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa • Permission has been obtained for use of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print or to be reproduced in color on the Web (free of charge) and in black-and-white in print
• If only color on the Web is required, black and white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at https://service.elsevier.com.

AFTER ACCEPTANCE
Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: http://www.adobe.com/products/reader/systemreqs. If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use
this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately - please let us have all your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

**Offprints**
The corresponding author will be notified and receive a link to the published version of the open access article on ScienceDirect. This link is in the form of an article DOI link which can be shared via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication.

**AUTHOR INQUIRIES**
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com